Fortress Biotech, Inc. (FBIO) Form 8-K Material Events
Fortress Biotech, Inc. (FBIO) is a publicly traded company on the Nasdaq, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: FBIO
CIK: 1429260
Exchange: Nasdaq
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: DE
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
KPMG LLP
Auditor SinceSince 12/31/2021 12:00:00 AM
Lead Engagement PartnerJoseph Epstein
Audit LocationNew York, New York, United States
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 8-K | 2026-10-01 | 2026-09-30 | 8-K | 0001104659-26-112845 | View SEC Doc Filr Page |
| 4 | 2026-10-01 | 2026-10-01 | 4 Filing | 0001930732-26-000006 | View SEC Doc Filr Page |
| SCHEDULE 13G | 2026-09-01 | — | SCHEDULE 13G Filing | 0001104659-26-104386 | View SEC Doc Filr Page |
| 10-Q | 2026-08-13 | 2026-06-30 | 10-Q | 0001104659-26-095964 | View SEC Doc Filr Page |
| 8-K | 2026-08-13 | 2026-08-13 | 8-K | 0001104659-26-095931 | View SEC Doc Filr Page |
| 4 | 2026-06-24 | 2026-06-22 | 4 Filing | 0001930732-26-000003 | View SEC Doc Filr Page |
| 8-K | 2026-06-23 | 2026-06-17 | 8-K | 0001104659-26-076811 | View SEC Doc Filr Page |
| SCHEDULE 13G/A | 2026-05-15 | — | SCHEDULE 13G/A Filing | 0000919574-26-003180 | View SEC Doc Filr Page |
| 10-Q | 2026-05-14 | 2026-03-31 | 10-Q | 0001104659-26-061233 | View SEC Doc Filr Page |
| 8-K | 2026-05-14 | 2026-05-14 | 8-K | 0001104659-26-061208 | View SEC Doc Filr Page |
| DEFA14A | 2026-04-28 | — | DEFA14A | 0001104659-26-050366 | View SEC Doc Filr Page |
| DEF 14A | 2026-04-28 | 2026-06-17 | DEF 14A | 0001104659-26-050358 | View SEC Doc Filr Page |
| 4 | 2026-04-01 | 2026-04-01 | 4 Filing | 0001930732-26-000002 | View SEC Doc Filr Page |
| 10-K | 2026-03-31 | 2025-12-31 | 10-K | 0001104659-26-037874 | View SEC Doc Filr Page |
| 8-K | 2026-03-31 | 2026-03-31 | 8-K | 0001104659-26-037749 | View SEC Doc Filr Page |
| 8-K | 2026-03-30 | 2026-03-30 | 8-K | 0001104659-26-036818 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-03-20 | — | SCHEDULE 13D/A Filing | 0001104659-26-032728 | View SEC Doc Filr Page |
| 4 | 2026-03-20 | 2026-03-18 | 4 Filing | 0000941841-26-000002 | View SEC Doc Filr Page |
| 4 | 2026-03-20 | 2026-03-18 | 4 Filing | 0001038977-26-000002 | View SEC Doc Filr Page |
| 8-K | 2026-02-23 | 2026-02-22 | 8-K | 0001104659-26-018371 | View SEC Doc Filr Page |
| 8-K | 2026-01-13 | 2026-01-13 | 8-K | 0001104659-26-003121 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-01-06 | — | SCHEDULE 13D/A Filing | 0001104659-26-001305 | View SEC Doc Filr Page |
| 4 | 2026-01-06 | 2026-01-02 | 4 Filing | 0001429260-26-000004 | View SEC Doc Filr Page |
| SCHEDULE 13D/A | 2026-01-05 | — | SCHEDULE 13D/A Filing | 0001104659-26-000690 | View SEC Doc Filr Page |
| 4 | 2026-01-05 | 2026-01-01 | 4 Filing | 0001647971-26-000002 | View SEC Doc Filr Page |